Skip to main content

Daniel Kelly Benjamin, MD, PhD

Kiser-Arena Distinguished Professor of Pediatrics
Professor of Pediatrics
Member in the Duke Clinical Research Institute
Campus mail: 7044 Duke Clinical Research Institute, 2400 Pratt St, Durham, NC 27710
Phone: (919) 668-7081

Dr. Danny Benjamin is the Principal Investigator and Chair of the National Institute of Child Health and Human Development’s Pediatric Trials Network. The Network is responsible for designing and leading clinical trials of off-patent medicines in children of all ages across all therapeutic areas. The team has established, or is actively studying, the correct dosing and safety of more than 50 of the most commonly used medicines in children. Each of these trials is conducted under an investigational new drug (IND) application with guidance from the Food and Drug Administration for labeling.

Signature programs of the Network include clinical trials in premature, term infants and most recently, obese children. Over the past 10 years, Dr. Benjamin’s group has enrolled more premature infants, at more sites, in more clinical trials of off-patent anti-infectives under an IND than all other academic medical centers, pharmaceutical companies, and government agencies in the world, combined.

Dr. Benjamin is recognized by the National Institutes of Health as a premiere mentor and educator. His research program serves as a platform to train students and early career investigators. Dr. Benjamin’s group has a clinical research summer program for high school and college students targeting under-represented minority students, and he is the primary mentor for medical students, residents, subspecialty fellows (including two T32 programs sponsored by NIH for which he is PI), and multiple junior faculty.

Dr. Benjamin has published over 250 works with up to 7000 citations. 

Education and Training

  • Fellow, Pediatric Infectious Diseases, Pediatrics, Duke University, 1998 - 2001
  • Resident, Pediatrics, Children's Hospital, 1995 - 1998
  • Ph.D., University of North Carolina at Chapel Hill, 2003
  • M.P.H., University of North Carolina at Chapel Hill, 2001
  • M.D., University of Virginia, 1995

Selected Grants and Awards

Publications

Gray, Keyaria D., Kathryn Dudash, Carla Escobar, Colman Freel, Tylah Harrison, Chandler McMillan, Mihai Puia-Dumitrescu, et al. “Prevalence and safety of diazoxide in the neonatal intensive care unit.” J Perinatol 38, no. 11 (November 2018): 1496–1502. https://doi.org/10.1038/s41372-018-0218-4.

Full Text

Benjamin, Daniel K., David A. Kaufman, William W. Hope, P Brian Smith, Antonio Arrieta, Paolo Manzoni, Laura L. Kovanda, et al. “A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis.” Pediatr Infect Dis J 37, no. 10 (October 2018): 992–98. https://doi.org/10.1097/INF.0000000000001996.

Full Text

Shakhnovich, Valentina, P. Brian Smith, Jeffrey T. Guptill, Laura P. James, David N. Collier, Huali Wu, Chad E. Livingston, et al. “A Population-Based Pharmacokinetic Model Approach to Pantoprazole Dosing for Obese Children and Adolescents.” Paediatr Drugs 20, no. 5 (October 2018): 483–95. https://doi.org/10.1007/s40272-018-0305-1.

Full Text

Wang, Laura A., P Brian Smith, Matthew Laughon, Ronald N. Goldberg, Lawrence C. Ku, Kanecia O. Zimmerman, Stephen Balevic, et al. “Prolonged furosemide exposure and risk of abnormal newborn hearing screen in premature infants.” Early Hum Dev 125 (October 2018): 26–30. https://doi.org/10.1016/j.earlhumdev.2018.08.009.

Full Text

Tsakiri, Sophia, Chiamaka Aneji, Christine Domonoske, Lynnette Mazur, Daniel K. Benjamin, and Susan H. Wootton. “Voriconazole Treatment for an Infant With Intractable Candida glabrata Meningitis.” Pediatr Infect Dis J 37, no. 10 (October 2018): 999–1001. https://doi.org/10.1097/INF.0000000000002073.

Full Text

Autmizguine, Julie, Sylvia Tan, Michael Cohen-Wolkowiez, C Michael Cotten, Nathan Wiederhold, Ronald N. Goldberg, Ira Adams-Chapman, et al. “Antifungal Susceptibility and Clinical Outcome in Neonatal Candidiasis.” Pediatr Infect Dis J 37, no. 9 (September 2018): 923–29. https://doi.org/10.1097/INF.0000000000001913.

Full Text

Thaden, Joshua T., Karen Chiswell, Ian Jaffe, Stephen P. Bergin, William E. Yang, Andrew Romaine, Jamie Roberts, et al. “Pediatric Antibacterial and Antifungal Trials From 2007 to 2017.” Pediatrics 142, no. 3 (September 2018). https://doi.org/10.1542/peds.2017-1849.

Full Text

Bernard, Gordon R., Paul A. Harris, Jill M. Pulley, Daniel K. Benjamin, Jonathan Michael, Daniel E. Ford, Daniel F. Hanley, Harry P. Selker, and Consuelo H. Wilkins. “A collaborative, academic approach to optimizing the national clinical research infrastructure: The first year of the Trial Innovation Network.” J Clin Transl Sci 2, no. 4 (August 2018): 187–92. https://doi.org/10.1017/cts.2018.319.

Full Text

Ariagno, Ronald L., Henry C. Lee, David K. Stevenson, Daniel K. Benjamin, P Brian Smith, Marilyn B. Escobedo, and Dilip R. Bhatt. “A directory for neonatal intensive care: potential for facilitating network-based research in neonatology.” J Perinatol 38, no. 8 (August 2018): 954–58. https://doi.org/10.1038/s41372-018-0097-8.

Full Text

Gonzalez, Daniel, Laura P. James, Amira Al-Uzri, Miroslava Bosheva, Felice C. Adler-Shohet, Susan R. Mendley, John S. Bradley, et al. “Population Pharmacokinetics and Safety of Solithromycin following Intravenous and Oral Administration in Infants, Children, and Adolescents.” Antimicrobial Agents and Chemotherapy 62, no. 8 (August 1, 2018). https://doi.org/10.1128/AAC.00692-18;e00692-18.

Full Text

Pages